Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more
Market Cap & Net Worth: Tiziana Life Sciences Ltd (TLSA)
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has a market capitalization of $165.42 Million ($165.42 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18786 globally and #6958 in its home market, demonstrating a -5.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tiziana Life Sciences Ltd's stock price $1.30 by its total outstanding shares 127247401 (127.25 Million).
Tiziana Life Sciences Ltd Market Cap History: 2018 to 2026
Tiziana Life Sciences Ltd's market capitalization history from 2018 to 2026. Data shows change from $187.92 Million to $165.42 Million (-3.24% CAGR).
Index Memberships
Tiziana Life Sciences Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #512 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1727 of 3165 |
Weight: Tiziana Life Sciences Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tiziana Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tiziana Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TLSA by Market Capitalization
Companies near Tiziana Life Sciences Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Tiziana Life Sciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Tiziana Life Sciences Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Tiziana Life Sciences Ltd's market cap moved from $187.92 Million to $ 165.42 Million, with a yearly change of -3.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $165.42 Million | -12.75% |
| 2025 | $189.60 Million | +114.02% |
| 2024 | $88.59 Million | +24.32% |
| 2023 | $71.26 Million | -6.43% |
| 2022 | $76.16 Million | -37.66% |
| 2021 | $122.16 Million | -52.05% |
| 2020 | $254.75 Million | +87.03% |
| 2019 | $136.21 Million | -27.52% |
| 2018 | $187.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tiziana Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $165.42 Million USD |
| MoneyControl | $165.42 Million USD |
| MarketWatch | $165.42 Million USD |
| marketcap.company | $165.42 Million USD |
| Reuters | $165.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.